Zhu Y, Wang X, Cui Y
… +3 more, Bai J, Zheng J, Fan Y
J BUON
· 2021 Nov · PMID 34812147
PURPOSE: The aim was to demonstrate the progression of glioma influenced by Vitamin C (VC) and the potential molecular mechanism. METHODS: Proliferative and migratory rates of U87 and U251 cells induced with 0, 50 and 10...PURPOSE: The aim was to demonstrate the progression of glioma influenced by Vitamin C (VC) and the potential molecular mechanism. METHODS: Proliferative and migratory rates of U87 and U251 cells induced with 0, 50 and 100 µM VC were examined by CCK-8 and Transwell assay, respectively. Clinical significance of SYNPO2 in glioma patients was analyzed. Relative level of SYNPO2 in VC-induced glioma cells was detected. By intervening SYNPO2, the involvement of SYNPO2 in the anti-cancer role of VC in inhibiting glioma cell phenotypes was finally confirmed. RESULTS: VC induction dose-dependently attenuated proliferative and migratory potentials of glioma cells. A low level of SYNPO2 indicated poor prognosis of glioma. Protein and mRNA levels of SYNPO2 were upregulated in glioma cells induced with VC. The inhibitory effects of VC on proliferative and migratory potentials of glioma cells were partially reversed by knockdown of SYNPO2. CONCLUSIONS: VC blocks glioma cells to proliferate and migrate by upregulating SYNPO2.
Erdogan B, Kostek O, Bekir Hacioglu M
… +6 more, Gokyer A, Kucukarda A, Ozcan E, Gokmen I, Uzunoglu S, Cicin I
J BUON
· 2021 · PMID 34761635
PURPOSE: To demonstrate whether early changes in systemic inflammatory markers are related with pazopanib treatment response in soft tissue sarcoma and renal cell carcinoma. METHODS: Forty-one patients with metastatic cl...PURPOSE: To demonstrate whether early changes in systemic inflammatory markers are related with pazopanib treatment response in soft tissue sarcoma and renal cell carcinoma. METHODS: Forty-one patients with metastatic clear cell renal carcinoma (mRCC) (n=22) and advanced stage soft tissue sarcoma (STS) (n=19) were assessed. Systemic inflammatory markers such as neutrophils, lymphocytes, c-reactive protein (CRP), mean platelet volume (MPV), lactate dehydrogenase (LDH) and neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at both baseline and 1-month of pazopanib treatment were obtained and their relation with the first radiological response about 3-months later after pazopanib treatment was evaluated. RESULTS: Disease control rate (DCR) at the first initial radiological evaluation was 58.5 % for all, it was 77.3% for the RCC group and 36.8% in the STS group. Serum neutrophil, NLR and CRP levels were significantly decreased from baseline in RCC patients who had DCR with pazopanib treatment. Also, serum CRP levels after pazopanib treatment was significantly lower in RCC patients who had DCR (+) rather than those who progressed. CONCLUSIONS: Early decline in serum CRP, neutrophil and NLR levels in RCC patients who received pazopanib at the first month was significantly associated with disease control, assuming a predictive role for the first radiological assessment. However, there was no significant association between change in serum inflammatory marker levels and disease control in STS patients.
Tsolakidis D, Kyziridis D, Kalakonas A
… +3 more, Limberis A, Hristakis C, Tentes AA
J BUON
· 2021 · PMID 34761634
PURPOSE: Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) is the standard treatment for tumors presented with peritoneal metastases (PM). Data in the literature abo...PURPOSE: Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) is the standard treatment for tumors presented with peritoneal metastases (PM). Data in the literature about the treatment of rare tumors with PM are limited and of low-quality. The aim of the study was to assess the outcome and safety of CRS and HIPEC for these tumors. METHODS: Patients with rare tumors with PM that underwent CRS and HIPEC between 2005-2018, were retrospectively analyzed. Clinical and histopathological variables were correlated to survival. RESULTS: 43 patients, mean age 55.7 ± 12.9 years, underwent 48 cytoreductions. The most frequent histopathologic type was sarcomatosis (31.3%). The majority of the patients (70.8%) had limited extent of peritoneal disease. Complete or near-complete cytoreduction was achieved in 83.3% of the cases. Severe morbidity was recorded in 12.6%. The median disease-free survival and overall survival were 11 and 63 months, respectively. Although the completeness of cytoreduction was found to be significantly related to survival, the extent of peritoneal carcinomatosis was the single prognostic factor. CONCLUSIONS: CRS followed by HIPEC is an effective and safe method in the treatment of rare tumors with PM. Further large, well-designed prospective studies are needed to validate these results.
Matovina Brko G, Popovic M, Jovic M
… +14 more, Radic J, Bodlovic Kladar M, Nikolic I, Vidovic V, Kolarov Bjelobrk I, Kukic B, Salma S, Litavski J, Petrovic N, Vranjkovic B, Roganovic T, Ruzic M, Dugandzija T, Popovic L
J BUON
· 2021 · PMID 34761633
PURPOSE: Recommendations and guidelines consider cancer patients a high-priority population for COVID-19 immunization. Vaccination process in Serbia began in January 2021 with four available vaccines. We have conducted a...PURPOSE: Recommendations and guidelines consider cancer patients a high-priority population for COVID-19 immunization. Vaccination process in Serbia began in January 2021 with four available vaccines. We have conducted a cross-sectional study investigating cancer patients' acceptability of anti SARS-COV2 vaccines. METHODS: The study included 767 patients with solid and hematologic malignancies treated at the Oncology Institute of Vojvodina, Serbia. During July and August 2021 patients filled in an individual paper questionnaire on anti SARS-COV2 vaccination acceptance, preferences, side effects and information origin. Data on treatment phase, diagnosis and treatment was collected from electronic health records. RESULTS: During the first six months of vaccination campaign in Serbia 41% (320/767) of the investigated oncology patients received COVID-19 vaccines. The median age of vaccinated patients was 65 years (28-84). Most of them (75%) were in active treatment of cancer. Half of the unvaccinated patients (52%) wish to get vaccinated after the end of their cancer treatment. Around 10% of the patients definitely refused vaccination. The majority of information on COVID-19 vaccines cancer patients got from their oncologist, television and newspapers. Side effects were reported by 10.93% of the patients after the first dose and 13,31% after the second dose. No serious side effects were reported. CONCLUSION: We have confirmed that patients are reluctant of receiving vaccine due to fear of side effects, especially during the active cancer treatment. However, real-world evidence and clinical trials data have gathered enough evidence to reassure any doubts of the patients and their oncologists on safety and efficacy of anti SARS-COV2 vaccines.
Stylianou C, Kalemikerakis I, Vastardi M
… +5 more, Kavga A, Margari N, Dokoutsidou E, Konstantinidis T, Govina O
J BUON
· 2021 · PMID 34761632
PURPOSE: To assess patient satisfaction from chemotherapy and investigate the effect of demographic factors, disease symptoms and treatment on satisfaction. METHODS: A non-randomized cross-sectional survey was conducted...PURPOSE: To assess patient satisfaction from chemotherapy and investigate the effect of demographic factors, disease symptoms and treatment on satisfaction. METHODS: A non-randomized cross-sectional survey was conducted on a sample of 100 patients undergoing chemotherapy at "Metaxa" Cancer Hospital, Piraeus, Greece for 6 months. A demographic data questionnaire, a Cancer Treatment Satisfaction Questionnaire (CTSQ) and visual analog scales were used to evaluate pain, anxiety, fatigue, and nausea while presence or absence of vomit were also assessed. RESULTS: The majority of the patients in the sample were men (51%), with a mean age of 58.5 ± 10.82 years. The mean value of expectations from treatment was 60.55, from treatment's satisfaction was 75.86 and from feelings about treatment's side effects was 44.56. The most serious symptoms were fatigue and anxiety (7.2 ± 1.95 and 6.71 ± 2.5, respectively). Statistical tests have shown that sub-dimensions of CTSQ are associated with pain, anxiety, fatigue, and nausea. CONCLUSIONS: Generally, chemotherapy meets patients' expectations with cancer. Symptoms such as fatigue, anxiety, pain, and nausea affect their satisfaction. Treatment's satisfaction can be improved by evaluating symptoms, which will lead to appropriate interventions.
Eraslan E, Ilhan Gulesen A, Yildiz F
… +3 more, Tufan G, Yalcintas Arslan U, Alkis N
J BUON
· 2021 · PMID 34761631
PURPOSE: To evaluate the effect of adding adjuvant ifosfamide/doxorubicin combination chemotherapy (CTX) to adjuvant radiotherapy (RT) on the survival in patients with surgically treated high-risk soft tissue sarcomas (S...PURPOSE: To evaluate the effect of adding adjuvant ifosfamide/doxorubicin combination chemotherapy (CTX) to adjuvant radiotherapy (RT) on the survival in patients with surgically treated high-risk soft tissue sarcomas (STSs). METHODS: The study included 69 patients (group A) receiving adjuvant RT and 74 patients (group B) receiving adjuvant CTX after adjuvant RT. RESULTS: The median relapse-free survival (RFS) was 18.2 months (95% CI, 11.9-43.4) in group A and 27.2 months (95% CI, 17.6-36.8) in group B (p = 0.004). The median overall survival (OS) was 45.6 months (95% CI, 26.4-64.8) in group A and 110.1 mo (95% CI, 44.3-175.8) in group B (p = 0.007). Receiving adjuvant CTX was an independent predictive factor for both RFS [HR: 0.482, (0.307-0.757), p = 0.002) and OS (HR: 0.549, [0.348-0.867], p = 0.010). CONCLUSION: There are conflicting literature data regarding the survival benefit of adjuvant CTX for surgically treated STSs. However, appropriate patient selection may provide a significant survival benefit in RFS and OS with CTX in the adjuvant treatment of high-risk STSs.
PURPOSE: To determine the relationship between inflammatory cell types in the microenvironment of papillary thyroid microcarcinoma (PTMC) and prognostic factors. METHODS: The previous diagnoses and subtypes-variants of 1...PURPOSE: To determine the relationship between inflammatory cell types in the microenvironment of papillary thyroid microcarcinoma (PTMC) and prognostic factors. METHODS: The previous diagnoses and subtypes-variants of 163 patients with papillary thyroid microcarcinoma were re-evaluated according to the 2017 WHO classification. The peritumoral lymphocyte, plasma cell, neutrophil, eosinophil, and mast cell density were classified as none (0.24 mm2), mild (0-10/0.24 mm2), moderate (10-50/0.24 mm2), and severe (˃50/0.24 mm2) under 40x magnification and the relationship with prognostic factors was investigated. RESULTS: There was a statistically significant relationship between tumor capsule invasion (p=0.024) and surgical margin (p=0.049) with mast cell infiltration. A statistically significant relationship was observed between tumor capsule invasion (p=0.0001) and the postoperative disease-free period (p=0.0001) with neutrophil cell infiltration. The postoperative disease-free period of those with neutrophil infiltration was statistically significantly shorter than that of those with no infiltration. The tumor diameter of those with no plasma cells was statistically significantly smaller than that of patients with plasma cells (p=0.003). CONCLUSIONS: Closer follow-up of patients with neutrophils, mast cells, and plasma cells, which have been found to be associated with poor prognostic factors in terms of recurrence, lymph node involvement, and distant metastasis, may increase survival.
PURPOSE: We aimed to clarify the relationship between microRNA-204-3p level and clinical indicators in pancreatic cancer patients, and to provide theoretical references for target therapy. METHODS: Quantitative real-time...PURPOSE: We aimed to clarify the relationship between microRNA-204-3p level and clinical indicators in pancreatic cancer patients, and to provide theoretical references for target therapy. METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to detect relative levels of microRNA-204-3p and MGAT1 in 60 paired pancreatic cancer tissues and adjacent normal ones. The relationship between microRNA-204-3p level and clinical indicators in pancreatic cancer patients was analyzed. MicroRNA-204-3p overexpression model was established in AsPC-1 and CFPAC-1 cells. Transwell and wound healing assay were carried out to illustrate the influence of microRNA-204-3p on the migratory potential in pancreatic cancer. Lastly luciferase assay and rescue experiments were performed to demonstrate the potential mechanism between microRNA-204-3p and MGAT1. RESULTS: MicroRNA-204-3p was lowly expressed in pancreatic cancer tissues. Low level of microRNA-204-3p predicted high rates of lymphatic metastasis and distant metastasis, as well as poor prognosis in pancreatic cancer patients. Overexpression of microRNA-204-3p inhibited pancreatic cancer cells to migrate in vitro. MicroRNA-204-3p could be targeted by MGAT1 through specific binding sites in the 3'UTR. A negative correlation between MGAT1 and microRNA-204-3p was identified in pancreatic cancer tissues. The interaction between MGAT1 and microRNA-204-3p was responsible for inhibiting metastasis of pancreatic cancer. CONCLUSIONS: MicroRNA-204-3p is closely linked to lymphatic metastasis, distant metastasis and prognosis in pancreatic cancer patients. It inhibits the migratory ability in pancreatic cancer cells via negatively regulating MGAT1 level.
Zhang X, Sun Y, Hou Z
… +6 more, Luo B, Li C, Jiang K, Liu J, Yao G, Tang J
J BUON
· 2021 · PMID 34761628
PURPOSE: The excision of plantar malignant melanoma frequently leads to wide skin defects on the plantar surface. This study aimed to investigate the advantages and feasibility of dermal regenerative template reconstruct...PURPOSE: The excision of plantar malignant melanoma frequently leads to wide skin defects on the plantar surface. This study aimed to investigate the advantages and feasibility of dermal regenerative template reconstructing plantar blemishes caused by malignant melanoma. METHODS: 28 patients identified with plantar malignant melanoma were included in this retrospective article. Eighteen patients received immediate skin grafts after wide excision skin graft (SG) group), whereas the remaining 10 patients were treated with dermal regenerative template (DRT) (Lando ®, Shenzhen TsingCare Medical Co. Ltd) 14 days before skin grafts (DRT group) and the postoperative survival rate in the two groups was analyzed. During the 6-month follow-up, we compared the scar index, plantar pain, and recurrent skin graft ulcer incidence on the skin grafts area. RESULTS: Postoperative survival rate in the DRT group (91.75% ± 7.64%) was higher than in the SG group (80.51% ± 7.17%). The DRT group showed less scar formation on Vancouver scar scale (VSS index): 3.40 ± 1.07 than the SG group (VSS index: 6.33 ± 0.68). The dermal regenerative template alleviated plantar pain and decreased the incidence of ulcer on the skin grafts area. CONCLUSIONS: The dermal regenerative template not only improves the survival rate of skin grafts but also alleviates scar condition, plantar pain and recurrent skin graft ulcer. This study provides a new reconstructive strategy in plantar skin defects after the excision of malignant melanoma.
Cousillas Castineiras A, Gallardo Martin E, Fernandez Montes A
… +10 more, Carmona Campos M, Covela Rua M, Salgado Fernandez M, Pellon Augusto ML, Martínez Lago N, Vidal Insua Y, Brozos Vazquez E, De La Camara J, Alonso Herrero A, Mendez Mendez JC
J BUON
· 2021 · PMID 34761627
PURPOSE: The neutrophil-to-lymphocyte ratio (NLR) is an accessible marker from a routine blood test. This study explored the prognostic and predictive value of a change in NLR (c-NLR) after chemotherapy, baseline NLR (bN...PURPOSE: The neutrophil-to-lymphocyte ratio (NLR) is an accessible marker from a routine blood test. This study explored the prognostic and predictive value of a change in NLR (c-NLR) after chemotherapy, baseline NLR (bNLR) and chemotherapy response, in metastatic gastric cancer (mGC) patients. METHODS: A total of 116 mGC patients treated between 2009 to 2019 at seven hospitals from Galician Research Group on Digestive Tumors (GITuD) were reviewed in a multicentre, ambispective and observational study. NLR was calculated and the optimal cut-off was defined as NLR=3.96 based on ROC method. NLR was determined at baseline and after two chemotherapy cycles in first line treatment. Change NLR was calculated as NLR after two chemotherapy cycles minus bNLR. The relation of bNLR and c-NLR to overall survival (OS) was evaluated by Kaplan-Meier method and compared by log-rank test. Dynamic Score (DScore) based on c-NLR and baseline NLR were correlated with OS and radiological response. Univariate, multivariate and chi-square analyses were performed. RESULTS: Median patient age was 68.7 years, and 66% were male. Univariate analysis showed OS correlation for bNLR ≥3.96 (5.97 vs 10.87 months, p=0.001), c-NLR increase (6.63 vs 10.34 months, p=0.021) and DScore (12.74 vs 7.68 vs 2.43 months, p<0.001). High DScore was associated with radiological progression after two cycles (x2=10.26, p=0.006). Multivariate analysis: bNLR ≥3.96 (HR=2.16, p=0.003) and c-NLR increase (HR= 2.36, p=0.003) were prognostic factors of poor OS. CONCLUSION: High bNLR and increased NLR after chemotherapy were associated with worse outcome. Dynamic measurement of NLR provides information for stratifying patients to guide optimal treatment.